As Bluebird Bio INC (BLUE) Market Valuation Declined, Shareholder Capital International Investors Has Lowered Its Position

bluebird bio, Inc. (NASDAQ:BLUE) LogoInvestors sentiment decreased to 1.27 in Q2 2019. Its down 0.43, from 1.7 in 2019Q1. It fall, as 30 investors sold BLUE shares while 63 reduced holdings. 35 funds opened positions while 83 raised stakes. 60.47 million shares or 0.32% more from 60.27 million shares in 2019Q1 were reported. Intl Investors, California-based fund reported 5.09M shares. First Personal Fincl Ser holds 0% or 46 shares. Capital holds 0.27% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 6.68 million shares. Moreover, Gam Holdg Ag has 0.25% invested in bluebird bio, Inc. (NASDAQ:BLUE). Bnp Paribas Arbitrage Sa holds 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 19,816 shares. The New York-based Millennium Management Limited Liability has invested 0.02% in bluebird bio, Inc. (NASDAQ:BLUE). Baillie Gifford And holds 0.57% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 4.22 million shares. Benjamin F Edwards & reported 0.01% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Century Companies has 522,765 shares for 0.07% of their portfolio. Credit Suisse Ag accumulated 351,033 shares. Bailard has 2,000 shares. Connecticut-based Cubist Systematic Strategies Ltd Liability has invested 0.1% in bluebird bio, Inc. (NASDAQ:BLUE). 8,620 were accumulated by Credit Agricole S A. Bancorp Of Ny Mellon stated it has 206,728 shares or 0.01% of all its holdings. Mitsubishi Ufj Trust And Banking reported 161,798 shares.

Capital International Investors decreased its stake in Bluebird Bio Inc (BLUE) by 0.6% based on its latest 2019Q2 regulatory filing with the SEC. Capital International Investors sold 30,866 shares as the company’s stock declined 6.01% . The institutional investor held 5.09M shares of the health care company at the end of 2019Q2, valued at $647.32M, down from 5.12 million at the end of the previous reported quarter. Capital International Investors who had been investing in Bluebird Bio Inc for a number of months, seems to be less bullish one the $5.80 billion market cap company. The stock increased 1.69% or $1.74 during the last trading session, reaching $104.85. About 801,134 shares traded or 32.14% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has declined 15.47% since September 13, 2018 and is downtrending. It has underperformed by 15.47% the S&P500.

Capital International Investors, which manages about $250.64 billion US Long portfolio, upped its stake in Fiserv Inc (NASDAQ:FISV) by 2.04 million shares to 13.02M shares, valued at $1.19 billion in 2019Q2, according to the filing. It also increased its holding in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 50,013 shares in the quarter, for a total of 5.62 million shares, and has risen its stake in Yandex Nv A (NASDAQ:YNDX).

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on November, 7. They expect $-3.41 EPS, down 24.91 % or $0.68 from last year’s $-2.73 per share. After $-3.55 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -3.94 % EPS growth.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: which released: “Canopy Needs Its Earnings to Answer These Key Questions – Nasdaq” on August 14, 2019, also with their article: “With Gaza war talk, Russia visit, Netanyahu fights on in election race – Nasdaq” published on September 12, 2019, published: “South Africa’s rand extends rally to 4-week high, stocks up – Nasdaq” on September 04, 2019. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: and their article: “FTSE 100 inches lower as miners, oil majors drag – Nasdaq” published on September 06, 2019 as well as‘s news article titled: “Thyssenkrupp to leave Germany’s blue chip index DAX, MTU Aero joins – Nasdaq” with publication date: September 05, 2019.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Among 2 analysts covering Bluebird Bio (NASDAQ:BLUE), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Bluebird Bio has $19100 highest and $122 lowest target. $149.67’s average target is 42.75% above currents $104.85 stock price. Bluebird Bio had 7 analyst reports since March 22, 2019 according to SRatingsIntel. The company was maintained on Tuesday, August 6 by Morgan Stanley. The firm has “Hold” rating by Cantor Fitzgerald given on Friday, March 22.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.